191 results match your criteria: "Centre des Tumeurs de l'Universite Libre de Bruxelles.[Affiliation]"
Ann Oncol
March 2006
Department of Médecine Interne and Laboratoire d'Investigations Cliniques H-J Tagnon, Centre des Tumeurs de l'Université Libre de Bruxelles, Bruxelles, Belgium.
Background: The aim of the study was to elaborate a predictive model for the duration of chemotherapy-induced neutropenia (CIN) allowing the identification of patients with a higher risk of complications, especially complicated febrile neutropenia, who might benefit from preventive measures.
Patients And Methods: A score ranging from 0 to 4 on the basis of expected CIN was attributed to each cytotoxic agent given as part of chemotherapy treatment in solid tumours for patients with febrile neutropenia (FN). The individual scores were combined into several overall scores.
Rev Med Brux
December 2005
Service de Médecine Interne et Laboratoire d'lnvestigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles.
Evidence-based medicine has become a requisite for novel therapies. It requires demonstration, in well performed clinical trials, that a benefit for the patients can be obtained by changing what is considered as a standard treatment. The present review deals with the clinical trials in the field of cancer therapy which have been published, during 2004, mainly in the New England Journal of Medicine (NEJM).
View Article and Find Full Text PDFB-ENT
February 2006
Department of Surgery, Centre des Tumeurs de l'Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium.
Background: Distant metastases in head and neck cancer are often to the lung, and rarely to the skin sites.
Method: To ascertain that a skin metastasis indicates a poor prognosis, a review was conducted of patients with head and neck cancer.
Results: Three out of seven patients had evidence of local recurrence at the time of development of the skin metastases, and three out of seven had evidence of distant metastases.
Breast
December 2005
Medical Oncology Clinic, Jules Bordet Institute, Centre des Tumeurs de l'Universite Libre de Bruxelles, Rue Heger-Bordet, 1, 1000-Brussels, Belgium.
The 2003 St. Gallen consensus panel divided the many available adjuvant chemotherapy (CT) regimens into those with "standard efficacy" (ACx4, CMFx6) and those with "superior efficacy" (FA(E)Cx6, CA(E)Fx6, A(E)-->CMF, TACx6, ACx4--> paclitaxel (P)x4 or docetaxel (D)x4) but also greater complexity, toxicity and cost. This paper will summarize the latest information on long-term side effects of the "superior" regimens and 5-year benefits reported in taxane trials, including those of a "new" sequential regimen, FECx3--> docetaxelx3.
View Article and Find Full Text PDFRev Med Brux
December 2004
Service de Médecine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles.
We have witnessed recently major progress in the legislation in favor of the rights of the patients and in support of a clinical investigation that would be more respectful of these rights. Nonetheless, the compassionate attitude between the physician and the patient remains the corner stone of the patient-physician relationship. Its quality requires a better awareness of the importance of such a relationship by the physicians and necessitates a specialised and continous education.
View Article and Find Full Text PDFActa Clin Belg
January 2005
Département de Médecine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgique.
Purpose: Graft-versus-host disease (GVHD) is one of the major complications of allogeneic bone marrow transplantation. Twenty-two patients, who had an allogeneic bone marrow transplantion at the Institute J. Bordet, developed a GVHD proven by a biopsy.
View Article and Find Full Text PDFBr J Cancer
January 2005
Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival.
View Article and Find Full Text PDFBr J Cancer
December 2004
Critical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party.
View Article and Find Full Text PDFRev Pneumol Clin
November 2004
Service des soins intensifs & Oncologie thoracique, Institut Jules-Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1, rue Héger-Bordet, B-1000 Bruxelles, Belgique.
Spectacular therapeutic progress for small cell lung cancer was obtained some thirty years ago with the introduction of polychemotherapy. Since when, except that which concerns radio-chemotherapy in the limited forms, the development of treatments has been relatively poor. Based on the analysis of published literature, the aim of this review is to discuss the research routes.
View Article and Find Full Text PDFBr J Cancer
November 2004
Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
Tamoxifen is the standard first-line endocrine therapy for breast cancer, but recent data indicate that it is likely to be replaced by the effective aromatase inhibitors (AIs), in both the metastatic and adjuvant settings. Aromatase inhibitors induce complete oestrogen deprivation that leads to clinically significant bone loss. Several ongoing or planned trials combine AIs with bisphosphonates, even more so that recent data reveal that clodronate may reduce the incidence of bone metastases and prolong survival in the adjuvant setting.
View Article and Find Full Text PDFAnn Oncol
February 2005
Department of Medicine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
Rev Laryngol Otol Rhinol (Bord)
October 2004
Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Clinique de Chirurgie Cervico-Faciale, I rue Héger Bordet, B-1000 Bruxelles, Belgique.
Introduction: The aim of this study was to evaluate the results of the initial surgical treatment and salvage treatment for advanced laryngopharyngeal cancer.
Methods: From 1984 to 1997, primary surgical treatment was undertaken in 60 patients. 75 patients underwent surgical salvage following radiotherapy.
Support Care Cancer
October 2004
Department of Médecine Interne and Laboratoire d'Investigations Cliniques, H-J Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Rue Héger Bordet 1, 1000 Brussels, Belgium.
Background: Febrile neutropenia (FN) remains a major dose-limiting complication among patients treated with chemotherapy. Haematopoietic colony stimulating factors (G-CSF and GM-CSF) made possible a significant improvement in the management of FN, both in the therapeutic and in the prophylactic approach. The use of antibiotic prophylaxis also permits a definite reduction of severe infections during neutropenia.
View Article and Find Full Text PDFRev Stomatol Chir Maxillofac
June 2004
Département de chirurgie, Institut Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1, rue Héger-Bordet 1000 Bruxelles, Belgique.
We report a case of prostate carcinoma metastatic to the mandible that had been initially suspected as being a primary tumor of the parotid. The initial symptom was hard swelling in the left parotid region. No pathologic fracture was diagnosed.
View Article and Find Full Text PDFInt J Antimicrob Agents
February 2004
Service de Médecine Interne et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgium.
The number of fungal infections is increasing, particularly in patients with cancer, and represent a major problem given the relatively poor response rates, especially for aspergillosis, and the high cost. Empirical therapy has become an accepted practice as delay in instituting therapy is clearly associated with increased morbidity and mortality. In terms of efficacy for the management of persistent febrile neutropenic patients, there is no convincing evidence that conventional amphotericin B (ampho B) is inferior to any other agent; the lipid formulations of ampho B provide similar efficacy with lower toxicity but at a much higher cost.
View Article and Find Full Text PDFSupport Care Cancer
April 2004
Critical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Rue Héger-Bordet, 1, 1000 Brussels, Belgium.
Objective: To evaluate the effectiveness of a specific oncologic scoring system-the ICU Cancer Mortality model (ICM)-in predicting hospital mortality in comparison to two general severity scores-the Acute Physiology and Chronic Health Evaluation (APACHE II) and the Simplified Acute Physiology Score (SAPS II).
Patients And Methods: All 247 patients admitted for a medical acute complication over an 18-month period in an oncological medical intensive care unit were prospectively registered. Their data, including type of complication, vital status at discharge and cancer characteristics as well as other variables necessary to calculate the three scoring systems were retrospectively assessed.
Oncology
December 2003
Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgique.
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications. Other preventive measures, such as amifostine or methylene blue administration, have not yet been adequately evaluated in a sufficient number of patients.
View Article and Find Full Text PDFSupport Care Cancer
November 2003
Intensive Care Unit (ASTI), Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
A 47-year-old man with acute lymphocytic leukemia was admitted in intensive care unit (ICU) because of respiratory failure. He had febrile neutropenia and probable invasive pulmonary aspergillosis (IA). Amphotericin B renal toxicity and clinical deterioration prompted a shift to caspofungin and resulted in a successful response.
View Article and Find Full Text PDFChest
July 2003
Service de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
Study Objectives: To determine the type of infections occurring in hospitalized patients with lung cancer.
Design: Prospective cohort study.
Setting: Department of internal medicine in a cancer hospital.
Support Care Cancer
May 2003
Service de Soins Intensifs (ASTI), Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Rue Heger-Bordet 1, 1000 Brussels, Belgium.
We describe the first case of spontaneous splenic rupture associated with tinzaparin in a cancer patient. This low-molecular-weight heparin was administrated for deep venous thrombosis and pulmonary embolism. No underlying splenic pathology predisposing to this condition was found.
View Article and Find Full Text PDFSupport Care Cancer
April 2003
Department of Medicine and Data Centre (Biostatistics Unit), Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Bruxelles, Belgium.
Objective: To determine prognostic factors predicting success of invasive mechanical ventilation in medical cancer patients admitted to ICU for a complication, in terms of extubation and ICU and hospital discharges.
Design: Retrospective study
Setting: Medical ICU of an European cancer hospital.
Subjects: A total of 168 consecutive cancer patients who were admitted to ICU for an acute medical complication requiring immediate mechanical ventilation or who later needed mechanical ventilation.
J Neurooncol
November 2002
Service de Médecine Interne et Laboratoire d'Investigations Cliniques, Centre des Tumeurs de l'Université Libre de Bruxelles, Bruxelles, Belgique.
We report the case of a 72-year-old woman suffering from bone metastatic breast cancer and treated with continuous intravenous 5 fluorouracil (5FU) chemotherapy, who presented with a bilateral asymmetric anterior optic neuropathy (ON). A deficiency of dihydropyrimidine dehydrogenase (DPD) was documented. Patients with DPD deficiency are at increased risk for developing unusual and/or severe toxicity to 5FU.
View Article and Find Full Text PDFSupport Care Cancer
February 2003
Department of Internal Medicine, Institut Jules Bordet, Centre des tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
In a 56-year-old man with metastatic small-cell lung cancer, a persistent hiccup was refractory to classic treatments. Hyponatremia, neoplasic mediastinal involvement and liver metastases were though to be potential causative factors. Methylphenidate (MTP), a mild central nervous system (CNS) stimulant that is most commonly used for the treatment of attention deficit hyperactivity disorder, was started at a daily dose of 10 mg.
View Article and Find Full Text PDFSupport Care Cancer
January 2003
Clinique des soins intensifs oncologiques et de la cancérologie pulmonaire, Départment de Médicine Interne, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
The objective of this retrospective study of prospectively registered patients was to determine the usefulness and efficacy of noninvasive ventilation (NIV) in cancer patients admitted to the medical intensive care unit of an European cancer hospital for a medical complication, as reflected in discharges from the intensive care unit (ICU) and from hospital. The subjects were a total of 40 consecutive cancer patients (28 with solid tumours and 12 with haematological malignancies) who required immediate or delayed NIV. Variables relating to demographic parameters, severity scores, cancer characteristics, intensive care data and hospital discharge were recorded.
View Article and Find Full Text PDFJ Chir (Paris)
September 2002
Département de Chirurgie, Institut Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles - Bruxelles, France.
Desmoid tumor can be defined as a pseudoencapsulated infiltrative growth of well-differentiated collagenous fibroblasts and fibrocytes arising either in fascia or musculoaponeurotic structures. The etiology of desmoid tumors is poorly defined. The most commonly implicated etiologic factors are trauma, hormonal disturbances, and genetic or hereditary factors.
View Article and Find Full Text PDF